John Vandermosten
@vanjohn10
Followers
2K
Following
79
Media
2K
Statuses
8K
Biotechnology Analyst, CFA. Cancer, Autoimmune and Neurodegenerative Diseases. Audaces fortuna iuvat.
Texas
Joined April 2009
Azitra addresses false report circulating that it had priced a $44mm offering. $AZTR asserts that this is untrue. The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni. https://t.co/chVYhdz8y4
ir.azitrainc.com
BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra , Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1
10
17
Rani Therapeutics reports 3Q *PR reiterates recent capital raise & Chugai deal *Plan start of RT114 trial before year end *2 new board members $RANI https://t.co/8m4OBxYmYa
finance.yahoo.com
Rani Therapeutics Holdings recently announced a collaboration and license agreement with Chugai Pharmaceutical for the joint development and commercialization of an oral product combining Rani’s...
0
1
4
It is difficult to have a conversation these days without bringing up Artificial Intelligence. Chief Commercial Officer Jaime Xinos shares how @achievelifesci will use AI to improve their commercialization activities. $ACHV https://t.co/pI64nqrdaK
1
0
1
Why is drug half life important & how does this impact the # of CTx-1301 doses needed? The principal investigator for @CingulateInc's trials, Dr. Ann Childress, explains how #ADHD medicines' half life can let symptoms return in the evening. $CING https://t.co/OJ9nkbzXke
0
0
1
Get ready for @achievelifesci's 3Q report on Thursday morning with a review of $ACHV balance sheet. CEO Rick Stewart talks about capital efficiency, how long funds will last and new sources of capital that look attractive. https://t.co/4zN8VpUasV
0
0
1
Reviva Pharmaceuticals will attend the Spartan Capital Securities conference 3Nov. To get you warmed up, here's Dr Bhat discussing Neuroinflammation: https://t.co/MlfBg1zVGd $RVPH https://t.co/mvKpGBCsd5
finance.yahoo.com
CUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
0
8
9
Reviva Pharmaceuticals CEO Dr Bhat covers several topics in a 🔥 chat. AI, financing considerations, M&A, IPOs, other trials in the CNS space and opinions on the equity markets for the year ahead. $RVPH https://t.co/xYLrfnV7SQ
#schizophrenia #biopharma #biotech
0
7
11
FDA accepts @LantheusNews' NDA for MK-6240, a PET imaging agent for tau in #Alzheimer's. *PDUFA date 13Aug26 $LNTH https://t.co/fz01orRRkZ Stay tuned for earnings next Thursday!
finance.yahoo.com
PDUFA Date Set for August 13, 2026BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to...
0
1
2
Dr. Ann Childress, principal investigator on @CingulateInc's CTx-1301 trials, highlights some of the differences in ADHD symptoms between children and adults. #ADHD #Neuroscience #Biotech #SmallCapBiotech #BiotechInvesting #ClinicalPipeline #DrugDevelopment #NASDAQ
0
6
8
Rani Therapeutics appoints Abe Bassan & Vasudev Bailey, PhD to board representing new investors Samsara & Anomaly. See Zacks' report for detail: https://t.co/cP5eG6e2ZW $RANI https://t.co/92inwFtsBW
finance.yahoo.com
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
0
1
4
Dr Ann Childress, principal investigator on #Cingulate CTx-1301 trials, comments on an article that finds an association between use of ADHD medication and lower suicide risk. $CING https://t.co/79TcyLoeO0
#ADHD #Biotech #DrugDevelopment #ADHDTreatment #NASDAQ
0
2
3
Today's the day! @azitrainc COO Travis Whitfill to present on the Dermatologic Rare Disease panel at Maxim Growth Summit *8:30 am *NYC *Netherton syndrome & Recessive Epidermolysis Bullosa Catch it while you can $AZTR https://t.co/dCGjUfW4tK
ir.azitrainc.com
BRANFORD, Conn. , Oct. 15, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
0
6
8
Dr. Ann Childress, principal investigator on @CingulateInc's CTx-1301 trials, shares a story about ADHD medications that only work for part of the day. $CING #Cingulate #ADHD #Neuroscience #Biotech #BiotechStocks #LifeSciences #NASDAQ
0
0
1
Dr. Ann Childress, PI for @CingulateInc's trials, describes how the new #ADHD medication CTx-1301 works in this brief clip. $CING #Cingulate #Biotech #ClinicalTrials #LifeSciences #ADHDResearch #BiotechInvesting #PharmaNews #NASDAQ
0
0
3
Rani Therapeutics $1B+ collab w/ Chugai Pharma for multiple indications in rare disease & immunology *$10mm upfront *$75mm tech xfer & dev milestones *Option for 5 more drugs *$60mm pvt placement also announced $RANI https://t.co/2mmyAhniwI
finance.yahoo.com
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit...
0
0
1
FDA accepts @CingulateInc NDA for CTx-1301 in ADHD. PDUFA date: 31May26. $CING https://t.co/U9lelDA8np
finance.yahoo.com
Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the FDA’s 505(b)(2) regulatory pathway KANSAS CITY,...
2
0
5
Chief Commercial Officer Jaime Xinos explains @achievelifesci’s strategy to deploy digital resources for maximum effect. $ACHV #SmokingCessation #ClinicalTrials #BiotechInnovation #LifeSciences #PublicHealth #AddictionResearch #TobaccoFreeFuture #HealthEquity #MedicalResearch
0
0
0
#ICYMI, @LexariaBioCorp #CEO Rich Christopher sat down with us earlier this week to get us up to speed on $LEXX. https://t.co/4jRa0J0lsL
@LexariaBioCorp engages life sciences biz development advisory firm *Expands $LEXX reach to additional DehydraTECH applications *Identity not disclosed *Announces 4 new patents https://t.co/y6IQIdXwU6
0
0
0
Join @LexariaBioCorp & its CEO Rich Christopher for a longer version of our interview where we look @ DehydraTECH, activity in the GLP-1 space & $LEXX work here. https://t.co/NjSViakjry
0
1
2
What is EQUIP-A-Pharma? This program was announced back in May and focuses on manufacturing & addressing national health security. @Geovax_News CEO David Dodd provides details. $GOVX https://t.co/eUHlX6tL85
0
0
0